Moderna has gotten torched over the last six months - since September 2024, its stock price has dropped 51.2% to $33.99 per ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

Biotechnology researchers at Rensselaer Polytechnic Institute (RPI) are working to further improve mRNA therapeutics, with ...

building on its own technology platform focused on mRNA therapeutics and expanding the breadth of its portfolio into new therapeutic classes. The company expanded its geographic footprint to ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics ...

Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst ...

The "mRNA Cancer Therapeutics Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com ...

indicating an all-time high global demand for mRNA vaccines and therapeutics. Now more than ever, robust process development and manufacturing are essential to ensure patients have access to life ...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8537 ...